Skip to main content

Page last checked

Research compound · not FDA-approved

Kisspeptin-10

Also written Kisspeptin 10.

Kisspeptin-10 is the ten-amino-acid working core of kisspeptin, the signal sitting at the very top of the reproductive hormone chain.

What matters first

Why people look it up
It is sold for libido, for fertility, and for raising testosterone.
What the evidence shows
The human work is physiology research in groups of four to six people, run to map the circuit rather than to treat anyone. Given into a vein it lifted luteinising hormone in men within half an hour. Given under the skin — the route these vials are sold for — it moved neither hormone in the women studied.
Dose status
Kisspeptin-10 is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Kisspeptin-10

Kisspeptin-10 is the ten-amino-acid core of kisspeptin, which starts a hormone signal in the reproductive system. Researchers gave it to healthy volunteers to study that signal, not to treat a condition. A dose into a vein raised luteinizing hormone in men within 30 minutes. Under-the-skin injection did not raise LH or FSH in women in the follicular phase of their cycle. Responses varied by sex and cycle phase, so these groups do not isolate the effect of route.

Kisspeptin-10 research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourcelimited human data
FDA approvalNot FDA-approved
Studied dosing41.7 mcg once per kilogram of body weight (published as 32 nmol/kg; the largest under-the-skin dose in the study did not raise either measured hormone in women sampled during the follicular phase) — from clinical trials
Studied dosing0.01–3 mcg once per kilogram of body weight (in healthy men, luteinizing hormone peaked at 1 mcg/kg; 3 mcg/kg produced a smaller response) — from clinical trials
Studied dosing1.5–4 mcg per kilogram per hour, infused for up to 22.5 hours in healthy men (the lower rate raised LH pulse frequency; the higher rate raised testosterone) — from clinical trials
Typical vials5 mg · 10 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

What the evidence for Kisspeptin-10 is

People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.

limited human data
What it establishes
It shows that people have received it and that some human information exists.
What it does not establish
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.

Evidence snapshot and shareable image

Evidence snapshot

Foreign approval or limited human data

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study3 reported dose rows
Safety evidence
No safety findings listedAn empty list does not establish safety
Sources
2 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
Kisspeptin-10 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Where Kisspeptin-10 is in clinical trials

5 registered studies; the program has reached phase 3. Nothing is currently open or enrolling.

  • Phase 3Completed

    Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

    Quaid-e-Azam University · Sterility, Reproductive · 15 participants · started August 2014

    Main measurement due August 2014

    NCT03315325 on ClinicalTrials.gov

  • Phase 3Completed

    Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

    Ghulam Nabi · Reproductive Physiological Phenomena · 30 participants · started June 2014

    Main measurement due August 2014

    NCT03286517 on ClinicalTrials.gov

  • Phase 3Completed

    KP-10 and Insulin Secretion in Men

    Quaid-e-Azam University · Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men · 14 participants · started October 2013

    Main measurement due November 2013

    NCT03771326 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-27

Every compound we track, and what stage each one has reached →

Regulatory status

University studies have given kisspeptin-10 to people under ethics review.

Their doses were scaled to body weight and used to map hormones, not to set a treatment dose. FDA placed it in category 2 of its interim 503A compounding policy on September 29, 2023. It is not on the withdrawn list.

An FDA committee reviewed it for low hormone function in men on October 29, 2024, but a review is not an approval.

Full regulatory tracker →

Where to go next on Kisspeptin-10

The related pages keep each topic with its evidence.

Why no Kisspeptin-10 reaction profile can be published

No human trial has published a Kisspeptin-10 reaction profile, so there are no reliable rates to show.

Doses per 5 mg Kisspeptin-10 vial in the Kisspeptin-10 reconstitution calculator

The nearest syringe line to the target, and the rounding error it introduces for Kisspeptin-10.

What each water volume does to the 10 mg Kisspeptin-10 vial

Every option for the 10 mg Kisspeptin-10 vial, with an example draw on a U-100 barrel.

Reconstituting Kisspeptin-10 at 5 mg, step by step

The 5 mg Kisspeptin-10 table itself, not a general rule applied to an unrelated vial size.

Who else is sold for testosterone besides Kisspeptin-10

What people take it for and what the testosterone page shows stay in separate columns, including Kisspeptin-10

The sexual function page Kisspeptin-10 appears on

0 of the 2 sexual function rows rest on reported use and nothing more, with Kisspeptin-10 as context

Every calculator on this site, Kisspeptin-10 and the rest

Every intermediate value is printed, for Kisspeptin-10 or any other vial.

What backs the Kisspeptin-10 numbers, and what backs the rest

Every row states whether a label, a trial or nothing stands behind it, including Kisspeptin-10

Which compounds are still in trials besides Kisspeptin-10

Compounds with no registered trial are counted as exactly that, including Kisspeptin-10

Kisspeptin-10 in the regulatory changelog

A proceeding with no published outcome is entered as exactly that, including Kisspeptin-10

Safety notes

  • Every human study dose was scaled to body weight. A flat number without a body weight is not the same dose.
  • The largest under-the-skin dose did not change LH or FSH in women sampled during the follicular phase.
  • The response varied by sex and menstrual-cycle phase; route alone does not explain the differences between groups.
  • In one dose-ranging arm, 3 mcg/kg produced a smaller luteinizing-hormone response than 1 mcg/kg.
  • These studies mapped hormone signals; they did not establish a treatment dose.
  • Study groups held four to six people, too few to detect uncommon harm.
  • The peptide starts a chain that affects several reproductive hormones.
  • An FDA committee reviewed it for low hormone function in men on October 29, 2024. A review is not an approval.
  • FDA placed it in category 2 of its interim 503A policy on September 29, 2023. FDA cited immune-reaction risk, impurities, and limited safety data.
  • Material sold online is not the pharmaceutical-grade product used in those studies.

Questions about Kisspeptin-10

Is Kisspeptin-10 FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Kisspeptin-10 taken?

Trials study it both by injection under the skin and by drip or injection into a vein. The table above keeps each route and schedule separate.

How does Kisspeptin-10 differ from the other compounds in this class?

Kisspeptin-10 has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about Kisspeptin-10?

It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

2primary sources, each with the day we read it — open the documents used on this page